News
CDTTW
0.0122
+19.61%
0.0020
Weekly Report: what happened at CDT last week (0504-0508)?
Weekly Report · 3d ago
CDT Equity Unit Sarborg Files Parent Covering Two Established Compounds Within The Cystic Fibrosis Market
Benzinga · 6d ago
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
TipRanks · 05/07 04:50
CDT advances AZD5904 into global PCT patent phase
PUBT · 05/06 12:32
Weekly Report: what happened at CDT last week (0427-0501)?
Weekly Report · 05/04 10:12
CDT Equity director Ulrik K. Olsen files initial beneficial ownership statement
PUBT · 05/01 00:17
CDT Equity Announces Board Changes and New Chairperson
TipRanks · 04/27 20:30
CDT Equity appoints Ulrik Olsen to board after Lewis-Hall resignation
PUBT · 04/27 20:12
CDT Equity management to meet with Maxim
TipRanks · 04/27 16:25
Weekly Report: what happened at CDT last week (0420-0424)?
Weekly Report · 04/27 10:14
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/24 21:05
CDT Equity files to sell 5.35M shares of common stock for holders
TipRanks · 04/22 10:10
CDT EQUITY - FILES FOR OFFERING OF UP TO 5.35 MLN SHARES OF COMMON STOCK - SEC FILING
Reuters · 04/22 10:05
CDT Equity management to meet with Maxim
TipRanks · 04/20 17:25
Weekly Report: what happened at CDT last week (0413-0417)?
Weekly Report · 04/20 10:11
CDT Equity publishes corporate presentation on AI-driven drug development and out-licensing strategy
PUBT · 04/16 16:16
CDT Equity expands multi-pathway value creation strategy across pharma, IP
TipRanks · 04/16 12:47
CDT Equity targets out-licensing growth via AI-driven indication discovery and solid-form IP
PUBT · 04/16 12:35
CDT Equity FY25 operating loss widens 139% to $36.8 million
PUBT · 04/15 21:02
What's Going On With CDT Equity Shares On Monday?
Benzinga · 04/13 16:38
More
Webull provides a variety of real-time CDTTW stock news. You can receive the latest news about CDT Equity Inc, through multiple platforms. This information may help you make smarter investment decisions.
About CDTTW
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).